share_log

Acelyrin | 8-K: ACELYRIN, INC. Announces Positive Phase 3 Data for Izokibep in Hidradenitis Suppurativa; Focuses Strategy on Lonigutamab and Reports Second Quarter 2024 Financial Results

Acelyrin | 8-K: ACELYRIN, INC. Announces Positive Phase 3 Data for Izokibep in Hidradenitis Suppurativa; Focuses Strategy on Lonigutamab and Reports Second Quarter 2024 Financial Results

Acelyrin | 8-K:ACELYRIN, INC.宣佈Izokibep治療化膿性汗腺炎的第三階段數據爲陽性;將戰略重點放在Lonigutamab上,並公佈2024年第二季度財務業績
美股SEC公告 ·  08/14 04:18
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息